Circulating tumor cells as prognostic marker in pancreatic cancer

doi:10.5306/wjco.v15.i2.165

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1399)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

WORD

HTML

700

Sum=751

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

166

Sum=261

Publishing Process of This Article

Item

Count

Browse

Download

236

Sum=334

Feb 24, 2024 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Feb 24, 2024; 15(2): 165-168
Published online Feb 24, 2024. doi: 10.5306/wjco.v15.i2.165

Circulating tumor cells as prognostic marker in pancreatic cancer

Melek Yakar, Durmuş Etiz

Melek Yakar, Department of Radiation Oncology, Osmangazi University, Eskişehir 26040, Turkey

Durmuş Etiz, Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir 26040, Turkey

Author contributions: Yakar M and Etiz D contributed to this paper; Yakar M designed the overall concept and outline of the manuscript; Etiz D contributed to the discussion and design of the manuscript; Yakar M and Etiz D contributed to the writing, and editing the manuscript, illustrations, and review of literature.

Conflict-of-interest statement: All the authors have no commercial associations or sources of support that might pose a conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Melek Yakar, MD, Adjunct Associate Professor, Radiation Oncology, Osmangazi University, Meşelik Campus Büyükdere District Prof. Dr. Nabi AVCI Boulevard No. 4 26040 Odunpazarı, Eskişehir 26040, Turkey. myakar@ogu.edu.tr

Received: December 3, 2023
Peer-review started: December 3, 2023
First decision: December 7, 2023
Revised: December 16, 2023
Accepted: January 9, 2024
Article in press: January 9, 2024
Published online: February 24, 2024
Processing time: 78 Days and 21.3 Hours

Core Tip

Core Tip: Pancreatic cancer is a cancer that is usually diagnosed at an advanced stage due to its late onset of symptoms and rapid progression, and therefore has a high mortality rate despite intensive treatments. Detecting patients at an earlier stage is important in terms of cure rates. Predicting occult metastases in radiologically resectable cases will prevent unnecessary surgery. Additionally, if the patient's prognosis can be predicted, different treatment strategies and even personalized treatments may come to the fore. Currently, there is no reliable biomarker for diagnosis, staging or prognosis prediction in pancreatic cancer. Circulating tumor cells are promising in this respect.